<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Castiello MC</submitter><funding>Intramural NIH HHS</funding><funding>Ministero dell’Istruzione, dell’Università e della Ricerca</funding><funding>Division of Intramural Research, National Institute of Allergy and Infectious Diseases</funding><pagination>309-320.e6</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC8322962</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>147(1)</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>Mutations in the recombinase-activating genes cause severe immunodeficiency, with a spectrum of phenotypes ranging from severe combined immunodeficiency to immune dysregulation. Hematopoietic stem cell transplantation is the only curative option, but a high risk of graft failure and poor immune reconstitution have been observed in the absence of myeloablation.&lt;h4>Objectives&lt;/h4>Our aim was to improve multilineage engraftment; we tested nongenotoxic conditioning with anti-CD45 mAbs conjugated with saporin CD45 (CD45-SAP).&lt;h4>Methods&lt;/h4>Rag1-KO and Rag1-F971L mice, which represent models of severe combined immune deficiency and combined immune deficiency with immune dysregulation, respectively, were conditioned with CD45-SAP, CD45-SAP plus 2 Gy of total body irradiation (</pubmed_abstract><journal>The Journal of allergy and clinical immunology</journal><pubmed_title>Efficacy and safety of anti-CD45-saporin as conditioning agent for RAG deficiency.</pubmed_title><pmcid>PMC8322962</pmcid><funding_grant_id>ZIA AI001222</funding_grant_id><pubmed_authors>Castiello MC</pubmed_authors><pubmed_authors>Villa A</pubmed_authors><pubmed_authors>Bosticardo M</pubmed_authors><pubmed_authors>Fontana E</pubmed_authors><pubmed_authors>Corsino C</pubmed_authors><pubmed_authors>Notarangelo LD</pubmed_authors><pubmed_authors>Sereni L</pubmed_authors><pubmed_authors>Yamazaki Y</pubmed_authors><pubmed_authors>Sacchetti N</pubmed_authors><pubmed_authors>Uva P</pubmed_authors><pubmed_authors>Palchaudhuri R</pubmed_authors><pubmed_authors>Calzoni E</pubmed_authors><pubmed_authors>Scadden DT</pubmed_authors><pubmed_authors>Bortolomai I</pubmed_authors><pubmed_authors>Draghici E</pubmed_authors><pubmed_authors>Yu HH</pubmed_authors></additional><is_claimable>false</is_claimable><name>Efficacy and safety of anti-CD45-saporin as conditioning agent for RAG deficiency.</name><description>&lt;h4>Background&lt;/h4>Mutations in the recombinase-activating genes cause severe immunodeficiency, with a spectrum of phenotypes ranging from severe combined immunodeficiency to immune dysregulation. Hematopoietic stem cell transplantation is the only curative option, but a high risk of graft failure and poor immune reconstitution have been observed in the absence of myeloablation.&lt;h4>Objectives&lt;/h4>Our aim was to improve multilineage engraftment; we tested nongenotoxic conditioning with anti-CD45 mAbs conjugated with saporin CD45 (CD45-SAP).&lt;h4>Methods&lt;/h4>Rag1-KO and Rag1-F971L mice, which represent models of severe combined immune deficiency and combined immune deficiency with immune dysregulation, respectively, were conditioned with CD45-SAP, CD45-SAP plus 2 Gy of total body irradiation (</description><dates><release>2021-01-01T00:00:00Z</release><publication>2021 Jan</publication><modification>2026-05-09T17:15:27.849Z</modification><creation>2022-02-11T00:53:19.1Z</creation></dates><accession>S-EPMC8322962</accession><cross_references><pubmed>32387109</pubmed><doi>10.1016/j.jaci.2020.04.033</doi></cross_references></HashMap>